Oral Vinorelbine for the Treatment of Metastatic Non-Small Cell Lung Cancer in Elderly Patients: A Phase II Trial of Efficacy and Toxicity.
Publication/Presentation Date
3-1-2004
Abstract
PURPOSE: Before now oral vinorelbine has not yet been tested in a cohort of elderly, advanced non-small cell lung cancer patients, even though the intravenous form of this drug provides a reasonable therapeutic option for this group. This trial was conducted to determine the tumor response rate and toxicity profile of oral vinorelbine in advanced non-small cell lung cancer patients > or = 65 years of age.
PATIENT AND METHODS: Fifty-eight evaluable patients > or = 65 years of age with advanced non-small cell lung cancer were enrolled. Median age was 73 years (range: 65-87). The Eastern Cooperative Oncology Group (ECOG) performance score was 0, 1, or 2 in 29, 59, and 12% of patients, respectively. All patients had adequate organ function. Oral vinorelbine 60 mg/m2 per week was prescribed weekly as first-line therapy.
RESULTS: Two patients manifested a confirmed tumor response, yielding a response rate of 3.4% (95% confidence interval (CI): 0.4, 11.9%). There were no complete responses. Median progression-free survival was 3.5 months (95% CI: 2.2, 5.4 months), and median overall survival was 7.5 months (95% CI: 5.0, 12 months). There were five deaths, one of which might have been treatment-related, and there were 10 grade 4 events.
CONCLUSIONS: Oral vinorelbine, as prescribed in this trial, provides minimal activity in the treatment of advanced non-small cell lung cancer in patients > or = 65 years of age.
Volume
43
Issue
3
First Page
345
Last Page
353
ISSN
0169-5002
Published In/Presented At
Kanard, A., Jatoi, A., Castillo, R., Geyer, S., Schulz, T. K., Fitch, T. R., & ... Kugler, J. W. (2004). Oral Vinorelbine for the Treatment of Metastatic Non-Small Cell Lung Cancer in Elderly Patients: A Phase II Trial of Efficacy and Toxicity. Lung Cancer (Amsterdam, Netherlands), 43(3), 345-353.
Disciplines
Medical Sciences | Medicine and Health Sciences
PubMedID
15165094
LVHN link
http://search.ebscohost.com/login.aspx?direct=true&db=mnh&AN=15165094&site=ehost-live&scope=site
Peer Reviewed for front end display
Peer-Reviewed
Department(s)
Department of Medicine, Hematology-Medical Oncology Division, Department of Medicine Faculty
Document Type
Article